



SciTech Development, LLC

FOR IMMEDIATE RELEASE


SciTech to Present at 2018 NYC Oncology Investor Conference

(GROSSE POINTE FARMS, MI) October 27, 2018 – SciTech Development, a clinical stage drug development company, announced today that its President, Earle Holsapple, will deliver a corporate presentation and meet with investors at the NYC Oncology Investor Conference 2018. The conference will take place on October 30-31, 2018 at the Venable Law Conference Center at Rockefeller Center in New York City.

Mr. Holsapple is scheduled to present on Wednesday, October 31st at 10:25 am EST. Accredited investors are also invited to request a one-on-one meeting with SciTech Development's management during the conference through the One-on-One Meeting Space.

SciTech is seeking funding to bring its lead product ST-001 to market for the treatment of T-cell non-Hodgkin's lymphoma (NHL) and small cell lung cancer (SCLC). ST-001 may be used as a standalone drug or as an ancillary treatment with immunotherapy. SciTech's product pipeline also includes treatment for several other cancer indications.

The company has submitted an Investigational New Drug (IND) Application for ST-001 in the treatment of NHL. The FDA has already granted Orphan Drug Status for ST-001 in the treatment of two types of NHL: peripheral T-cell lymphoma (PTCL) and cutaneous T-cell lymphoma (CTCL).

Information regarding SciTech's nano formulation technology and oncology drug product ST-001 is available from SciTech Development, LLC by calling (313) 938-5517 or online at <https://www.scitechdevelopment.com/> and  .

About SciTech Development

SciTech Development, LLC is a clinical stage oncology drug company currently bringing to market a proven cancer drug for diseases with otherwise limited therapeutic options. SciTech

Development is headquartered in the Metropolitan Detroit Michigan Area with laboratories at the Sinai Hospital BioIncubator in Baltimore Maryland.

Selected Product Pipeline

- ST-001 – Intravenous fenretinide formulation for the treatment of NHL.
- ST-002 – Topical formulation for the treatment of various skin cancers and bed sores.
- ST-003 – Intravenous formulation for the treatment of small cell lung cancer (SCLC).
- ST-004 – Intravenous formulation for the treatment of metastatic breast cancer (MBC).
- ST-005 – Intravenous formulation for the treatment of neuroblastoma (pediatric cancer).
- ST-006 – Intravenous formulation for the treatment of T-cell acute lymphoblastic leukemia (T-ALL).

About The NYC Oncology Investor Conference

The NYC Oncology Investor Conference 2018 hosted by OneMed Forum, and sponsored by the National Foundation for Cancer Research, the International Cancer Impact Fund, Klosters Innovation Partners, Venable Law Firm, Torrey Partners, and Marcum is the leading conference for early-stage private and public cancer investing. More information is available from the conference website (<https://www.nyconcolgyconference.com/>).

Forward-Looking Information

This press release and linked information contains forward-looking statements, including information about management's view of SciTech Development LLC (“the Company”), future expectations, plans and prospects. In particular, the words “believes,” “expects,” “intends,” “plans,” “anticipates,” or “may,” and similar conditional expressions are intended to identify forward-looking statements. Any statements made in this release and linked information other than those of historical fact, about an action, event or development, are forward-looking statements. These statements involve known and unknown risks, uncertainties and other factors, which may cause the results of the Company, its subsidiaries and concepts to be materially different than those expressed or implied in such statements. Unknown or unpredictable factors also could have material adverse effects on the Company’s future results. The forward-looking statements included in this press release and linked information are made only as of the date hereof. The Company cannot guarantee future results, levels of activity, performance or achievements. Accordingly, you should not place undue reliance on these forward-looking statements. Finally, the Company undertakes no obligation to update these statements after the date of this release, except as required by law, and also takes no obligation to update or correct information prepared by third parties that are not paid for by SciTech Development LLC.

For More Information: Earle T. Holsapple, President
SciTech Development, LLC
(313) 938-5517



####